| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Phase II RCT published in NEJM (2023). Phase III program underway but not yet completed. Single well-designed RCT — not yet multiple Phase III. |
20 / 25 |
| Sample Size | Phase II enrolled 338 participants across dose cohorts. Meaningful for Phase II but small by metabolic drug standards. |
8 / 20 |
| Replication | Single Phase II study. No independent replication yet — Phase III data pending. Score reflects current state, not projected. |
5 / 20 |
| Journal Impact Factor | Phase II results published in NEJM (IF ~96). A-journal primary data from day one. |
15 / 15 |
| Funding Independence | Eli Lilly funded Phase II. Pre-registered NCT trial but entirely industry funded with no independent academic replication yet. |
3 / 10 |
| Population Diversity | Phase II had reasonable but not exceptional diversity — predominantly US population, mixed sex. Moderate score. |
3 / 5 |
| Researcher h-Index | Lora Heisler and Jeff Emmerson as key investigators; Eli Lilly authors with strong institutional profiles. |
5 / 5 |